A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Ohio State University
Hoffmann-La Roche
Arvinas Inc.
Myeloid Therapeutics
xCures
DualityBio Inc.
Zhejiang University
Seagen Inc.
West China Hospital
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Alaunos Therapeutics
Massive Bio, Inc.
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Travera Inc
Elicio Therapeutics
TCR2 Therapeutics
TCR2 Therapeutics
Jonsson Comprehensive Cancer Center
Alaunos Therapeutics
Alaunos Therapeutics
University Hospital, Angers
Telix Pharmaceuticals (Innovations) Pty Limited
NextPoint Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
Tongji Hospital
Instituto do Cancer do Estado de São Paulo
Merus B.V.
Janssen Research & Development, LLC
Elevation Oncology
Singlera Genomics Inc.
Zymeworks BC Inc.
Symphogen A/S
ABM Therapeutics Shanghai Company Limited
Travera Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
University of California, San Diego
Convalife (Shanghai) Co., Ltd.
ABM Therapeutics Corporation
TransThera Sciences (Nanjing), Inc.
Beijing Kejing Biotechnology Co., Ltd.
Beijing Friendship Hospital
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
NextCure, Inc.
Universitair Ziekenhuis Brussel